Gilead Sciences Elvitegravir Phase III trial meets primary objective
The Phase III 48-week clinical trial evaluating the non-inferiority of Elvitegravir versus Raltegravir each administered with a background regimen in HIV-infected treatment-experienced adults with HIV RNA (viral load)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.